BioChemInsights announces exclusive North American Distributorship for Becker & Associates Databases

The world's leading provider of Life Science Molecule Databases

January 3, 2000   -  Malvern, Pa USA & Paris, FRANCE

Dr. William B. Armiger, President of BioChemInsights & Dr. Abram Becker, President of Becker & Associates announced today the signing of a long-term license & distributorship agreement establishing BCI as the exclusive North American distributor for B&A CD-ROM Databases & Publications. 

B&A is the world's leading provider of Life Science Molecule Databases.  These powerful database tools provide leading-edge data on the chemistry & markets for over 4,500 Bio-Active Molecules linked to more than 21,000 intermediates used in:

• Pharmaceutical Intermediates & Actives
• Developmental Drugs
• Generic Drugs
• Agrochemicals

In the joint announcement, Drs. Armiger & Becker stated that "Data Mining the Becker Databases generates information for both business & technical decision making.  Our clients gain valuable perspectives on commercial drugs & products in the drug developmental pipeline.  Through the  critical analyses of the chemistries & markets for bio-active molecules, our clients identify early business trends & opportunities for commercial & developmental pharmaceutical intermediates & actives."

Becker & Associates is a company specializing in the analysis & development of pharmaceuticals, pesticides & fine chemical production.  Founded in Paris in !994, its main activities include research & development, chemical technology & market studies, & publication of leading-edge databases for Life Science Molecules.

BioChemInsights offers advisory services to "Manage Knowledge for Strategic Business Decisions" by providing leading edge tools for information systems & data mining.  BCI works with its clients to analyze & understand industry trends in pharmaceuticals drug development linked to fine chemicals & biotechnology.  The company provides high-level strategic planning for business growth related to leveraging technology or identifying, analyzing & pursuing acquisition opportunities. Its due diligence activities draw upon its expertise & insights in understanding & valuing the interactions between chemistry & biology in drug development & drug candidate screening from bioprocessing & metabolic engineering to combinatorial chemistry, high-throughput screening, proteomics, & bioinformatics.

BCI offers its clients an unequalled breadth & depth of experience to help them expand their knowledge capital & discover new paths to sustained performance in life science businesses.